Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mologen to start Phase I study of cancer drug
The study will be carried out in cancer patients to test the safety, compatibility and immunological impact of MGN1703. Patients who suffer from the most commonly occurring cancers
The study will be carried out in cancer patients to test the safety, compatibility and immunological impact of MGN1703. Patients who suffer from the most commonly occurring cancers
Under the terms of the agreement, Merck will be granted access to Spin Signal Technology (SST) utilizing hyperpolarized Xenon 129 gas, a molecular imaging agent that is under
The notes pay an 8% coupon, have a three year maturity and a conversion price of $2.65 a share. The aggregate net proceeds of the notes, after deducting
N30 intends to develop N30-201 for the treatment of reactive and obstructive airway diseases, including cystic fibrosis and asthma. The primary endpoint of the study is patient safety
VantageCath is designed to significantly reduce exposure to bloodborne pathogens during the placement of the catheter and also provide the clinician with desirable feature sets. Existing safety engineered
The consideration is subject to adjustments based on ConvaTec’s audited 2007 financial statements and closing working capital. The closing, which is subject to customary regulatory approvals, is anticipated
Also investing in this financing were existing investors Galen Partners, Sycamore Ventures, Amkey Ventures, Lexli Investment, and Eminent Venture Capital. Cardiva also announced that Rick Anderson, a managing
The patent-pending modular forceps and accessories are designed to provide surgeons added comfort while reducing per-procedure costs through the reduction of inventory and obsolescence. The proprietary instruments offer
Under the company’s collaboration agreement with GlaxoSmithKline (GSK), Epix is entitled to receive a $7.5 million milestone payment from GSK related to the start of the Phase IIb
Lumenis ophthalmic unit has been streamlined to report to Gideon Sturlesi, who will lead the unit for the present time in addition to his role as Lumenis’s corporate